Valvular & structural heart diseaseDiagnostic or prognostic study
TRIVALVE Score
- Risk score derivation and internal validation study (registry-based)
- multisite registry
- multivariable logistic regression
- bootstrapping with 1,000 resamples
Authors' conclusion
The present study proposes a dedicated risk score for patients undergoing TTVI, providing an additional and simple tool for heart teams to select the best therapy for patients affected by severe TR.
Study context
- Population
- Patients with severe tricuspid regurgitation (TR) undergoing transcatheter tricuspid valve intervention (TTVI) (TRIVALVE registry)
- Participants
- 483 patients
- Outcome
- Mortality or rehospitalization
- Follow-up
- 12 months
Performance
As reported in the abstract
Risk score performance for 12-month mortality or rehospitalization
- Overall 12-month mortality or rehospitalization rate
- 19% (n = 94)
- Score range
- 0 to 4.5
- Score parameters (adjusted for age and gender): AF at baseline; GFR <30 mL/min; elevated gamma-glutamyl transferase/bilirubin; signs of right HF; LVEF <50%
- 5
- Bias-corrected AUC
- 68% (95% CI: 62%-75%)
- Cutoff 2.5 sensitivity
- 65.4%
- Cutoff 2.5 specificity
- 60.5%
Original publication
TRIVALVE Score. JACC Cardiovasc Interv. Published 23 September 2024. doi:10.1016/j.jcin.2024.08.009
Summarised from the published abstract; every number is checked against it